Core Viewpoint - The Law Offices of Frank R. Cruz is investigating BlackRock TCP Capital Corp. for potential violations of federal securities laws, indicating concerns over the company's compliance and financial practices [1]. Investigation Details - The investigation is initiated on behalf of investors who may have suffered financial losses related to BlackRock TCP Capital Corp. [1]. - The specific date mentioned for the investigation's context is January 23, 2026, which suggests a timeline for potential developments or disclosures [1].

Core Viewpoint - Halper Sadeh LLC is investigating the fairness of the sale of Stellar Bancorp, Inc. to Prosperity Bancshares, Inc. for 0.3803 shares of Prosperity common stock and $11.36 in cash per share of Stellar common stock, focusing on whether the transaction is fair to Stellar shareholders [1]. Group 1: Investigation Details - The investigation aims to determine if Stellar Bancorp and its board violated federal securities laws or breached fiduciary duties by not securing the best possible consideration for shareholders [1]. - Key concerns include whether Prosperity is underpaying for Stellar and if all material information necessary for shareholders to assess the merger consideration has been disclosed [1]. Group 2: Legal Representation - Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures, and other relief related to the proposed transaction [1]. - The firm operates on a contingent fee basis, meaning shareholders would not incur out-of-pocket legal fees or expenses [1].

Core Viewpoint - Halper Sadeh LLC is investigating the fairness of the sale of Gold Resource Corporation to Goldgroup Mining Inc. for 1.4476 common shares of Goldgroup for each share of Gold Resource common stock [1] Group 1: Investigation Details - The investigation focuses on whether Gold Resource and its board of directors violated federal securities laws and/or breached their fiduciary duties to shareholders [3] - Key concerns include whether the best possible consideration was obtained for shareholders, if Goldgroup is underpaying for Gold Resource, and whether all material information necessary for shareholders to assess the merger consideration was disclosed [3] Group 2: Legal Actions - Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures, and other relief related to the proposed transaction [4] - The firm operates on a contingent fee basis, meaning shareholders would not be responsible for out-of-pocket legal fees or expenses [4] Group 3: Firm Background - Halper Sadeh LLC represents investors globally who have been victims of securities fraud and corporate misconduct, recovering millions for defrauded investors [5]

Company Overview - Wealthfront Corporation is described as a technology company that has developed a financial solutions platform aimed at addressing the needs of wealth builders among digital natives [2]. Investigation Details - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Wealthfront, focusing on whether the company and certain executives made materially false and/or misleading statements or omitted material information regarding Wealthfront's business and operations [1][2]. Law Firm Background - Robbins Geller is recognized as one of the leading law firms in the world for representing investors in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in securities-related class action cases in 2024 alone [3]. - The firm has been ranked 1 in the ISS Securities Class Action Services rankings for four out of the last five years, indicating a strong track record in obtaining monetary relief for investors [3].

Core Viewpoint - Bgin Blockchain Limited is under investigation for potential violations of federal securities laws following significant financial losses and changes in auditor engagement [1][2][3]. Financial Performance - Bgin Blockchain Limited reported a decline in total revenue of approximately $96 million for the six months ending June 30, 2025, compared to the previous year [2]. - The company's operating expenses surged by 582.8%, leading to a gross loss of $6.3 million, a stark contrast to the gross profit of $84.8 million reported in the prior year [2]. Auditor Engagement - On December 15, 2025, Bgin announced it would not renew its current auditor and instead approved the engagement of a new independent registered public accounting firm effective December 12, 2025 [3]. - Following this announcement, Bgin's shares experienced a significant drop of over 59% on December 29, 2025 [3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Inovio Pharmaceuticals and its officers/directors, following a significant stock price drop after FDA news regarding its drug application [1][3][4]. Group 1: Investigation Details - Pomerantz LLP is representing investors of Inovio Pharmaceuticals, urging them to contact the firm regarding potential claims [1]. - The investigation focuses on whether Inovio and its executives have engaged in securities fraud or other unlawful practices [1]. Group 2: FDA Announcement and Stock Impact - On December 29, 2025, the FDA accepted Inovio's Biologics License Application for INO-3107 but indicated that the company did not provide sufficient information for accelerated approval [3]. - Inovio announced it would not pursue approval under the standard review timeline and plans to meet with the FDA to discuss options for accelerated approval [3]. - Following this announcement, Inovio's stock price fell by $0.56, or 24.45%, closing at $1.73 per share [4].

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of RAPT Therapeutics, Inc. (NASDAQ: RAPT) to GSK plc for $58.00 per share is fair to RAPT shareholders. Halper Sadeh encourages RAPT shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether RAPT and its board of directors violated th ...

Core Insights - Corcept Therapeutics Incorporated is under investigation for potential violations of federal securities laws following a Complete Response Letter (CRL) from the FDA regarding its new drug application for relacorilant [1][2] - The FDA's decision was based on the need for additional evidence of effectiveness despite acknowledging previous trial results [2] - Following the announcement, Corcept's stock price experienced a significant drop of $31.42, or 44.76%, reaching a new 52-week low of $38.78 per share [2][3] Company Developments - The FDA's CRL was issued on December 31, 2025, denying approval for relacorilant as a treatment for hypertension secondary to hypercortisolism [1] - The stock price decline marks a significant downturn, with levels not seen since September 2024 [3] Legal Context - Levi & Korsinsky LLP has initiated an investigation into Corcept, indicating potential legal ramifications for the company and its investors [1][4] - The firm has a strong track record in securities litigation, having secured substantial recoveries for shareholders in the past [4]

Core Viewpoint - The law firm Kirby McInerney LLP is investigating Soleno Therapeutics, Inc. for potential violations of federal securities laws or unlawful business practices related to its product Vykat XR [1]. Group 1: Company Performance and Events - On August 15, 2025, Scorpion Capital published a report labeling Soleno's Vykat XR as overpriced and potentially unsafe for children, leading to a share price decline of $5.73, or approximately 7.41%, from $77.36 to $71.64 [3]. - During a quarterly earnings call on November 4, 2025, Soleno disclosed that the discontinuation rate of Vykat XR due to adverse effects was around 8% at the end of Q3 2025. The CEO noted a disruption in the product's launch trajectory following the Scorpion Capital report, resulting in a further share price drop of $16.98, or approximately 26.59%, from $63.85 to $46.87 [4].

Core Viewpoint - Block & Leviton is investigating Travere Therapeutics, Inc. for potential securities law violations following a significant drop in its stock price after the FDA extended the review timeline for its drug FILSPARI [2][4]. Group 1: Company Overview - Travere Therapeutics, Inc. is facing scrutiny after its shares were halted from trading due to a more than 30% decline in intraday trading on January 13, 2026 [2]. - The U.S. FDA has set a new PDUFA target action date of April 13, 2026, for the supplemental New Drug Application for FILSPARI, indicating that additional data is required to assess clinical benefits [2]. Group 2: Investigation Details - Block & Leviton is examining whether Travere Therapeutics adequately disclosed the risks associated with the FDA review extension and if prior communications were misleading [2][4]. - The firm is considering filing an action to recover losses for investors who have been affected by the stock price decline [4]. Group 3: Investor Eligibility - Any investor who purchased common stock of Travere Therapeutics and experienced a loss may be eligible to participate in the investigation, regardless of whether they have sold their shares [3]. Group 4: Whistleblower Information - Individuals with non-public information about Travere Therapeutics are encouraged to assist in the investigation or report to the SEC under the whistleblower program, with potential rewards of up to 30% of any successful recovery [6]. Group 5: Firm Reputation - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].